ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2119

Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity

Winnie Liu1, Jeffrey Curtis2, Lars Folkestad3, Emily Holladay4, Jingyi zhang2, Shanette Daigle5, Ye Liu2, Fenglong Xie6 and Eric Orwoll1, 1Oregon Health and Science University, Portland, OR, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Southern Denmark, Odense, Denmark, Odense, Denmark, 4Foundation for Advancing Science Technology Education and Research, Hoover, AL, 5Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, 6The University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2025

Keywords: Bone density, Fracture

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility caused by mutations related to type 1 collagen biosynthesis. Fractures are a cardinal manifestation of OI, but fracture incidence across the lifespan is poorly understood. We used a large US-based cohort to describe fracture rates in individuals living with OI, stratified by clinical severity.

Methods: Individuals with OI were identified by ICD-9 (756.5) and/or ICD-10 (O78.0) diagnosis codes among ~30 million people included in MarketScan claims data (2006-2022) and a 5% random sample of US Medicare Fee-for-Service data (2006-2021). Severe OI was defined by long-term wheelchair use, identified using durable medical equipment (DME) claims. Incident fractures were identified using an adaptation of a previously validated algorithm with high specificity.

Results: We included 6,475 individuals with OI. Median age was 21.0 years (IQR: 8.0, 43.0) and severe OI was present in 20%. A reference cohort (N&#3f32,375) was matched 5:1 within each data source to those with OI by age, sex, race, index calendar year, and baseline length of continuous coverage. Median follow-up time was 2.1 years (IQR: 0.9, 4.5) in OI and 2.0 years (IQR: 0.8, 4.3) in the comparator group. In OI, the overall fracture rate was 129.6 (95% Cl: 124.7, 134.6) per 1000 person-years (py) vs 8.0 (95% CI: 7.4, 8.6) in the reference cohort (incidence rate ratio (IRR): 16.2, 95% Cl: 15.0, 17.2). Across all ages, the fracture rates were higher in severe vs milder OI (IRR: 238.6, 95% CI: 226.1, 251.7) vs 87.8 (95% CI: 83.2, 92.8) per 1000py (Figure 1). In both sexes, fracture rates were highest in childhood and lowest in early adulthood. In women with milder OI, fracture rates were highest at age 51 years and older, which coincides with the typical age range of menopause. In women with severe OI, the rates of fracture also increased in those aged 51 years and older. In men with milder OI fracture rates were stable with increased age, but were higher in older men with severe OI.

Conclusion: We report fracture rates stratified by sex, age and clinical severity in one of the largest datasets ever assembled of US individuals living with osteogenesis imperfecta. These data provide unique and necessary information for the clinical care of individuals living with OI and for the design of trials for new therapeutics.

Supporting image 1


Disclosures: W. Liu: None; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, Bendcare, 5, Bristol-Myers Squibb(BMS), 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, FASTER, 2, 4, Genentech, 2, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5, Moderna, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Sanofi, 2, 5, UCB, 2, 5; L. Folkestad: None; E. Holladay: None; J. zhang: None; S. Daigle: None; Y. Liu: Amgen, 5; F. Xie: None; E. Orwoll: amgen, 2, Angitia, 2, AstraZeneca, 2, bayer, 2, Biocon, 2, radius, 2, Ultragenyx, 2.

To cite this abstract in AMA style:

Liu W, Curtis J, Folkestad L, Holladay E, zhang J, Daigle S, Liu Y, Xie F, Orwoll E. Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/fracture-rates-in-6475-individuals-with-osteogenesis-imperfecta-stratified-by-age-sex-and-clinical-severity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fracture-rates-in-6475-individuals-with-osteogenesis-imperfecta-stratified-by-age-sex-and-clinical-severity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology